India to Launch First Approved Dengue Vaccine Qdenga in 2027

Key Points

• Qdenga (TAK-003) is a live-attenuated tetravalent dengue vaccine, meaning it targets all four dengue virus serotypes.

• The vaccine received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) in July 2026.

• It is approved for people aged 4–60 years and is given in two doses three months apart.

• Dr. Reddy’s Laboratories will distribute Qdenga in India’s private market under an agreement with Takeda Pharmaceuticals.

• Is the vaccine developed in India ? No, it was originally created by scientists at the U.S. Centers for Disease Control and Prevention (CDC) and fully developed, trialed, and manufactured by the Japanese multinational Takeda Pharmaceutical Company